ProShare Advisors
ONCT

ProShare Advisors’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

ProShare Advisors’s Portfolio ONCT Stock Details ONCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-574
Closed -$55K – 2326
2021
Q2 		$55K Buy
+574
New +$68.1K ﹤0.01% 2354
2014
Q2 		– Sell
-19
Closed -$41K – 2644
2014
Q1 		$41K Buy
+19
New +$47.3K ﹤0.01% 2720
2013
Q4 		– Sell
-28
Closed -$78K – 1950
2013
Q3 		$78K Buy
28
+7
+33% +$34.8K ﹤0.01% 2468
2013
Q2 		$193K Buy
+21
New +$162K ﹤0.01% 2056

Other funds holding ONCT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
ACM
ACT Capital Management Wayne, Pennsylvania $153M AUM
BJL
Brighton Jones LLC Seattle, Washington $2.37B AUM 16.36% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return

ProShare Advisors's ONCT Position: Q3 2021 in Review

ProShare Advisors sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q3 2021, closing a stake of 574 shares — an estimated $55K sold.

ProShare Advisors first reported a position in ONCT in Q2 2013 and held it in 4 quarters. The position peaked at $193K in Q2 2013. 76 funds tracked by Wall St. Rank hold ONCT as of Q3 2021.

  • ProShare Advisors reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
  • ProShare Advisors sold 574 Oncternal Therapeutics, Inc. Common Stock shares in Q3 2021, an estimated $55K.
  • ProShare Advisors first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q2 2013 and held it in 4 quarters.
  • ProShare Advisors's Oncternal Therapeutics, Inc. Common Stock position peaked at $193K in Q2 2013.
  • 76 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q3 2021.

Based on ProShare Advisors's 13F filing for Q3 2021, filed 12 Nov 2021.